Sculptra vs Lanluma

Sculptra and Lanluma are both PLLA products, but they should not share an assumed preparation or treatment protocol. Their vial presentations, public documentation, marketed use context, and regional labels must be checked separately.

This comparison describes identifiable product fields. It is not a head-to-head clinical ranking, and no direct comparative trial is used here to declare a winner.

Compact comparison

Field	Sculptra	Lanluma
Material	PLLA microparticles	PLLA
Publicly documented presentation	150 mg PLLA per dry vial	Lanluma V: 210 mg PLLA; Lanluma X: 630 mg PLLA
Preparation	Current global IFU: 5–8 mL sterile water; optional 1 mL 2% lidocaine	Use the exact presentation- and market-specific current IFU
Early appearance	Reconstitution fluid can cause temporary fullness	Reconstituted-product appearance should not be treated as the final response
Company context	Galderma	Sinclair

Sculptra data above come from Galderma’s global IFU version 4.7 (Sculptra IFU 🔗). Lanluma vial amounts are stated in Sinclair’s surgeon leaflet (Lanluma leaflet 🔗).

Why vial amount is not a dose conversion

The PLLA amount helps identify the presentation, but it does not create a direct conversion between products. Final suspension volume, concentration, hydration, anatomical plan, and label-specific instructions all matter.

Do not infer that:

• a larger vial is intended for every anatomical area
• equal milligrams produce equal tissue distribution
• Sculptra preparation volumes apply to Lanluma
• a commercial face-or-body category replaces the local approved indication

Documentation and use context

Sculptra has a current global IFU and a substantial US FDA approval history. Its permitted indications and wording still vary by market.

Sinclair presents Lanluma in face and body treatment contexts on regional professional pages (Sinclair Lanluma 🔗). That commercial framing is useful for identifying the product family, but it is not a universal authorization for every anatomical use.

A prospective, open-label post-market study reported Lanluma use across several body and neck areas. It had no untreated control and reported treatment-related lumps and nodules among adverse events, so it should be read as product-specific observational evidence rather than proof of superiority or a universal body protocol (Lanluma post-market study 🔗).

Chairside questions

For either product, confirm:

1. exact vial and local market label
2. reconstitution and hydration instructions
3. permitted additions and final use window
4. intended plane and anatomical indication
5. staged assessment interval
6. traceable lot, training, and company role

Same polymer, separate instructions

PLLA is the shared material. It does not make the products interchangeable, and neither product’s IFU should be used to fill gaps in the other’s documentation.

Practitioner takeaway

Choose and document the exact presentation before discussing technique. Read Sculptra and Lanluma separately, then use the PLLA vs PDLLA page only for the broader material distinction.